MedAvail : Corporate Presentation

Corporate Presentation

Safe Harbor Statements

MedAvail Holdings, Inc. ("MedAvail") cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by use of the words such as "anticipate," "believe," "expand," "expect," "grow," "intend," "opportunity," "plan," "potential," "project", "target" and "will" among others. These forward-looking statements are based on MedAvail's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of the ability to project future cash utilization and resources need for contingent future liabilities and business operations, the availability of sufficient resources for combined company operations and to conduct or continue planned product development activities, the ability to execute on commercial objectives, regulatory developments and the timing and ability of MedAvail to raise additional capital to fund operations, and other factors , including, but not limited to, those factors discussed in the section entitled "Risk Factors" of our Current Report on Form 10-K filed on March 31, 2021 and on Form 10-Q filed on November 9, 2021. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. We undertake no obligation to update any of these forward-looking statements for any reason, even if new information becomes available in the future, except as may be required by law. The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts MedAvail's businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. MedAvail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

MedAvail Current Snapshot

INVESTMENT HIGHLIGHTS

~$16.5B initial TAM - Medicare Part D revenue across 5,800 clinics in initial 6 states1

81 total embedded sites; 46 deployed in 2021

Proprietary technology platform enables on-site pharmacy at the point of care which is increasingly essential for value-based care delivery

7 SpotRx hub pharmacies; 1 deployed in 2021

4 states; 1 new in 2021 (Florida)

Highly scalable hub and spoke delivery model

20+ Medicare clinic partners; 8 new in 2021

Improves economics for at-risk Medicare providers

Appointed new CEO and CFO with Rx industry experience

Embedded in the growth algorithm of top Medicare clinic operators in key markets

Near-term market expansion opportunities with further pharmacy management systems integrations

$22.1M total 2021 revenue; 138% YOY growth

1 .Internal estimates based on 2017 CMS Medicare Provider Utilization and Payment Data: Part D Prescriber

BUSINESS UPDATE

Initial Target Markets - Estimated $16.5B1 of Annual Prescription Revenue

$16.5B Annual Rx

Spend across 5,800 clinics in 6 states

"TotalMarket"

$16.5B1

~700 clinics with current SpotRx partners in 4

states

Est. Opportunity

"Today's Market"

within 5,800 large clinics (~700 based on existing partners)

seeing ~6.5M Medicare

patients/year

~$500M2

serviceable

revenue in

today's current

core market

• 1 Internal estimates based on 2017 CMS Medicare Provider Utilization and Payment Data: Part D Prescriber

• 2 Internal estimates based on clinic qualification model and projected patient adoption rate

Meeting the Needs of Medicare Patients and Clinic Providers

Large, Growing MARKET

Medicare Enrollment

76M

65M

54M

50%

31%

34%

2015

2019

2025

All Other Medicare

Medicare Advantage

Source: Kaiser Family Foundation; LEK Insights

Significant VALUE

On multiple medications

GROSS PROFIT/RX

MedicareCommercialMedicaid

# of 90 DAY Rxs/YEAR

(5 = avg)

VALUABLE	HIGHLY VALUABLE
LOW VALUE
MODERATE VALUE

0

5

10

15

20

25

30

Concentrated VALUE

10% of patients drive 60% retail pharmacy industry gross margins

60%

10%

Moderate Value

Patients	Revenue	Gross Profit
Low Value	Valuable
Highly Valuable